Polyamine-Based Nanostructures Share Polyamine Transport Mechanisms with Native Polyamines and Their Analogues: Significance for Polyamine-Targeted Therapy.

cancer therapy drug delivery system drug transport nanoparticle nanopolyamine polyamine polyamine analogue polyamine transport

Journal

Medical sciences (Basel, Switzerland)
ISSN: 2076-3271
Titre abrégé: Med Sci (Basel)
Pays: Switzerland
ID NLM: 101629322

Informations de publication

Date de publication:
22 08 2022
Historique:
received: 30 06 2022
revised: 11 08 2022
accepted: 17 08 2022
entrez: 23 8 2022
pubmed: 24 8 2022
medline: 25 8 2022
Statut: epublish

Résumé

Polyamines are small polycationic alkylamines involved in many fundamental cellular processes, including cell proliferation, survival, and protection from oxidative stress. Polyamine homeostasis is tightly regulated through coordinated biosynthesis, catabolism, and transport. Due to their continual proliferation, cancer cells maintain elevated intracellular polyamine pools. Both polyamine metabolism and transport are commonly dysregulated in cancer, and as such, polyamine analogues are a promising strategy for exploiting the increased polyamine requirement of cancer cells. One potential polyamine analogue resistance mechanism is the downregulation of the poorly defined polyamine transport system. Recent advances in nanomedicine have produced nanostructures with polyamine analogue-based backbones (nanopolyamines). Similar nanostructures with non-polyamine backbones have been shown to be transported by endocytosis. As these polyamine-based nanoparticles could be a method for polyamine analogue delivery that bypasses polyamine transport, we designed the current studies to determine the efficacy of polyamine-based nanoparticles in cells lacking intact polyamine transport. Utilizing polyamine transport-deficient derivatives of lung adenocarcinoma lines, we demonstrated that cells unable to transport natural polyamines were also resistant to nanopolyamine-induced cytotoxicity. This resistance was a result of transport-deficient cells being incapable of importing and accumulating nanopolyamines. Pharmacological modulation of polyamine transport confirmed these results in polyamine transport competent cells. These studies provide additional insight into the polyamine transport pathway and suggest that receptor-mediated endocytosis is a likely mechanism of transport for higher-order polyamines, polyamine analogues and the nanopolyamines.

Identifiants

pubmed: 35997336
pii: medsci10030044
doi: 10.3390/medsci10030044
pmc: PMC9397040
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Polyamines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : R01 CA204345
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA235863
Pays : United States

Références

J Cell Physiol. 1990 Jun;143(3):460-7
pubmed: 2113535
Mol Pharm. 2012 Jun 4;9(6):1654-64
pubmed: 22545813
J Chromatogr. 1986 Jul 11;380(1):19-32
pubmed: 3745383
Cancer Res. 1988 Feb 15;48(4):759-74
pubmed: 3123052
Adv Enzyme Regul. 1988;27:57-79
pubmed: 3250233
J Biol Chem. 2021 Jan-Jun;296:100182
pubmed: 33310703
J Biol Chem. 2020 Jul 3;295(27):9061-9068
pubmed: 32430398
Int J Biochem. 1990;22(3):211-8
pubmed: 2110083
Nature. 2020 Feb;578(7795):419-424
pubmed: 31996848
IUBMB Life. 2009 Sep;61(9):880-94
pubmed: 19603518
Materials (Basel). 2020 Jan 13;13(2):
pubmed: 31941006
Invest New Drugs. 2001;19(1):29-39
pubmed: 11291831
Macromol Biosci. 2013 Jul;13(7):913-20
pubmed: 23629923
Nat Rev Cancer. 2004 Oct;4(10):781-92
pubmed: 15510159
J Biol Chem. 2008 Sep 26;283(39):26428-35
pubmed: 18660501
J Med Chem. 2003 Jun 19;46(13):2672-82
pubmed: 12801231
Cell Mol Life Sci. 2009 Sep;66(17):2873-96
pubmed: 19499185
Invest New Drugs. 1997;15(3):227-34
pubmed: 9387045
Biomolecules. 2021 May 10;11(5):
pubmed: 34068700
Sci Rep. 2022 Mar 8;12(1):4045
pubmed: 35260637
ACS Appl Mater Interfaces. 2022 Mar 9;14(9):11078-11091
pubmed: 35196008
J Drug Target. 2014 Jan;22(1):23-33
pubmed: 23987131
Mol Carcinog. 2008 Jul;47(7):538-53
pubmed: 18176934
Int J Mol Sci. 2022 Jun 18;23(12):
pubmed: 35743239
Mol Pharm. 2015 Feb 2;12(2):332-41
pubmed: 25153488
J Control Release. 2017 Jan 28;246:110-119
pubmed: 28017891
Am J Physiol. 1982 Nov;243(5):C212-21
pubmed: 6814260
J Biol Chem. 2004 Nov 19;279(47):49355-66
pubmed: 15208319
J Med Chem. 2000 Jan 27;43(2):224-35
pubmed: 10649978
J Med Chem. 2008 Apr 24;51(8):2551-60
pubmed: 18363351
J Med Chem. 2001 Jan 4;44(1):1-26
pubmed: 11141084
Cancer Chemother Pharmacol. 2008 Dec;63(1):45-53
pubmed: 18301893
J Cell Physiol. 1996 Jan;166(1):43-8
pubmed: 8557774
J Med Chem. 1998 Nov 19;41(24):4723-32
pubmed: 9822543
Nat Rev Cancer. 2018 Nov;18(11):681-695
pubmed: 30181570
Mol Cancer Ther. 2020 Oct;19(10):2012-2022
pubmed: 32747421
Cancer Chemother Pharmacol. 2013 Dec;72(6):1305-14
pubmed: 24121453
Cancer Lett. 1982 May-Jun;16(1):71-79
pubmed: 6811130
Cancer Chemother Pharmacol. 2020 Jun;85(6):1089-1096
pubmed: 32447421
Clin Cancer Res. 2002 Mar;8(3):684-90
pubmed: 11895896
Med Sci (Basel). 2021 May 13;9(2):
pubmed: 34068137
Mol Pharm. 2018 Feb 5;15(2):369-376
pubmed: 29299930
J Med Chem. 2014 Jan 23;57(2):348-63
pubmed: 24405276
Am J Physiol Gastrointest Liver Physiol. 2010 Aug;299(2):G517-22
pubmed: 20522643
Proc Natl Acad Sci U S A. 1968 Aug;60(4):1420-7
pubmed: 4299947
Microbiol Rev. 1985 Mar;49(1):81-99
pubmed: 3157043
J Biol Chem. 1995 Jan 27;270(4):1685-94
pubmed: 7829504
Med Sci (Basel). 2022 Jul 15;10(3):
pubmed: 35893120
J Biol Chem. 2003 Nov 21;278(47):47181-9
pubmed: 12972423
Cancer Chemother Pharmacol. 2009 Dec;65(1):191-5
pubmed: 19685053
Cancer Res. 1984 Oct;44(10):4382-5
pubmed: 6432312
Amino Acids. 2004 Jul;26(4):353-65
pubmed: 15290341
Chem Soc Rev. 2017 Jul 17;46(14):4218-4244
pubmed: 28585944
Cancer Res. 1992 Apr 1;52(7):1840-7
pubmed: 1551114

Auteurs

Cassandra E Holbert (CE)

Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.

Jackson R Foley (JR)

Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.

Ao Yu (A)

Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Cancer Center, Omaha, NE 68105, USA.

Tracy Murray Stewart (T)

Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.

Otto Phanstiel (O)

Department of Medical Education, University of Central Florida, Orlando, FL 32827, USA.

David Oupicky (D)

Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Cancer Center, Omaha, NE 68105, USA.

Robert A Casero (RA)

Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH